Skip to content
Menu

Relmada Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate. Cash and Equivalents $202.1M.

Benzinga Newsdesk 1 week ago

NewsEarningsEarnings Beats

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 60 percent increase over losses of $(0.30) per share

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 60 percent increase over losses of $(0.30) per share from the same period last year.

Read at benzinga.com